Regulus Therapeutics Inc To Host Special Update Call Transcript

Sep 20, 2023 / 12:30PM GMT
Operator

Good morning, and welcome to the Regulus Therapeutics Program Update. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to the company's CFO, Cris Calsada. Cris, please go ahead.

Crispina Calsada - Regulus Therapeutics Inc. - CFO

Thanks, operator. Good morning, and thank you for joining us for the special update on top line results from the first cohort of patients in our Phase Ib multi-ascending dose clinical trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease.

Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning Regulus Therapeutics' future expectations, plans, prospects, corporate strategy and performance, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot